PIN1 and acute promyelocytic leukemia: All-trans retinoic acid (ATRA) and arsenic trioxide (ATO), recently discovered to inhibit PIN1 (166, 176), are the most attractive compounds to be rapidly repurposed as PIN1 inhibitors in clinical trials, being already FDA approved and showing efficacy against acute promyelocytic leukemia (APL) both alone and in combination.